Dibenzoyl Thiamine

CAS No. 299-88-7

Dibenzoyl Thiamine ( Bentiamine )

Catalog No. M21353 CAS No. 299-88-7

Dibenzoyl Thiamine a lipophilic derivative of vitamin B (thiamine) is a kind of food additive.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 45 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Dibenzoyl Thiamine
  • Note
    Research use only not for human use.
  • Brief Description
    Dibenzoyl Thiamine a lipophilic derivative of vitamin B (thiamine) is a kind of food additive.
  • Description
    Dibenzoyl Thiamine a lipophilic derivative of vitamin B (thiamine) is a kind of food additive.
  • Synonyms
    Bentiamine
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    299-88-7
  • Formula Weight
    490.6
  • Molecular Formula
    C26H26N4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:98 mg/mL (199.76 mM)
  • SMILES
    CC1=NC=C(C(=N1)N)CN(C=O)/C(=C(/CCOC(=O)C2=CC=CC=C2)\SC(=O)C3=CC=CC=C3)/C
  • Chemical Name
    Benzenecarbothioic acid S-(2-(((4-amino-2-methyl-5-pyrimidinyl)methyl)formylamino)-1-(2-(benzoyloxy)ethyl)-1-propenyl) ester

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Heywood R Wood JD Majeed SK.Tumorigenic and toxic effect of OS-dibenzoyl thiamine hydrochloride in prolonged dietary administration to rats.Toxicol Lett. 1985 Jul;26(1):53-8
molnova catalog
related products
  • Ofatumumab

    Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation.

  • GIP (1-39)

    Endogenous truncated form of the incretin hormone GIP. More potent at stimulating glucose-dependent insulin secretion from rat pancreatic β-cells than GIP.

  • Remimazolam

    Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?